TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
SNO 2023 poster: |
Press Release2024, March 05 08:00 a.m. TME Pharma announces FDA clearance of Investigational New Drug (IND) application for NOX-A12 Phase 2 trial in brain cancer 2024, February 23 08:00 a.m. TME Pharma provides results of final exercise of Warrants Y: Additional €854k raised and extension of cash runway from May into July 2024 2024, February 09 08:00 a.m. TME Pharma announces the end of the convertible debt program with the successful €1.48 million financing intended for buyback of all outstanding convertible debt |
EventsBio Europe Spring 2024
Ewelina Staniuk, Dirk Eulberg 5th Annual Glioblastoma Development Summit
Aram Mangasarian (Panel Speaker) |